LAIR1 and familial pancreatic carcinoma: Combining anti-PD-1 antibodies with LAIR-1 inhibitors significantly improves treatment outcomes, as LAIR-1 blockade enhances CD4+ and CD8+ T-cell infiltration, potentiating anti-PD-L1 therapy in humanized xenograft models of colon and pancreatic cancer [131, 132].